Caption Management’s Stoke Therapeutics STOK Stock Holding History

Caption Management’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.51M	Buy	+200,000	New	+$6.56M	0.04%	450
2025 Q4	–	Sell	-60,000	Closed	-$1.41M	–	2044
2025 Q3	$1.41M	Buy	+60,000	New	+$1.03M	0.01%	984

Other funds holding STOK

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Caption Management's STOK Position: Q1 2026 in Review

Caption Management opened a new position in Stoke Therapeutics (STOK) in Q1 2026: 35,174 shares worth $1.15M. The stake represents 0.01% of the portfolio and ranks #981 among its holdings.

196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

Caption Management held 35,174 shares of Stoke Therapeutics worth $1.15M as of Q1 2026.
Stoke Therapeutics was a new Caption Management position in Q1 2026.
Stoke Therapeutics made up 0.01% of Caption Management's portfolio in Q1 2026, its #981 holding.
196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.